Natco Pharma Limited
LIC initiated a new position in Natco Pharma, acquiring 40,09,317 shares, representing a 2.24% stake. The investment is valued at ₹385.54 Cr based on Natco Pharma's share price of ₹961.60.
A vertically integrated pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. Natco Pharma operates across three core business segments: finished dosage formulations, active pharmaceutical ingredients, and contract manufacturing services. The company maintains a strong research and development focus to drive innovation and develop specialized therapeutic solutions across oncology, cardiovascular, gastroenterology, and other critical therapeutic domains.
India's largest domestic institutional investor with over Rs 56 lakh crore in total AUM, of which roughly Rs 15 lakh crore sits in listed equities. Holds stakes in virtually every major listed Indian company. When LIC builds or exits a position, it moves markets. Government-owned and mandated to invest policyholder funds in Indian equities and bonds, making it the ultimate long-only, long-term India bull.